营收利润双增长，销售及土地拓展规模稳中有升 2025 年 08 月 28 日 ➢ 营收规模受益于物业开发及金茂服务提升，扣非归母净利同比小幅提升。截 至 2025 年上半年，公司实现 251.13 亿元营收，同比提升 14%，主要系物业开 发及金茂服务收入较 2024 年上半年增加所致，其中土地及物业开发实现 200.41 亿元营收，同比提升 17%，金茂服务实现 17.83 亿元营收，同比提升 20%；截 至 2025 年上半年，公司实现 11.23 亿元扣非归母净利，同比提升 2%，主要系 营销及管理费用较上年同期各减少 15%和 5%所致。 ➢ 四大产品线全面升级，助力销售规模首进第一梯队。公司通过全面升级"金 玉满堂"四大产品线，在北京、上海及西安等重点城市发力，截至 2025 年上半 年，实现全口销售金额 533.5 亿元，同比 2024 年的 446.2 亿元提升 16.36%， 销售排名提升三位至全国第 9 位，首次跻身全国第十；公司在做优增量的同时， 进一步盘活存量，2025 年 1 月份公司以 7.81 亿元的价格，将湖州南太湖的 4 宗 土地出让给湖州南太湖管委会，实现了土地收储的探索。 ...

Investment Rating - The report maintains a "Recommended" investment rating for China Pacific Insurance (02328.HK) with a target price of HKD 21.5 [1][8]. Core Views - The company achieved a net profit of CNY 24.5 billion in H1 2025, representing a year-on-year increase of 32.3%. The original premium income rose by 3.6% to CNY 323.3 billion, while the combined ratio (COR) improved by 1.4 percentage points to 94.8%. The total investment return rate (unannualized) increased by 0.2 percentage points to 2.6% [1][8]. - The report highlights strong underwriting profitability and favorable investment conditions contributing to performance growth. The company plans to distribute an interim dividend of CNY 0.24 per share (before tax) [1][8]. Financial Performance Summary - In H1 2025, original premium income increased by 3.6% to CNY 323.3 billion, with a combined ratio (COR) of 94.8%, down 1.4 percentage points year-on-year. The loss ratio rose by 1.7 percentage points to 71.8%, while the expense ratio decreased by 3.1 percentage points to 23% [8]. - The company’s investment assets grew by 5.2% to CNY 711.5 billion by the end of H1 2025, benefiting from structural market conditions in equities and opportunities in the bond market [8]. - The report projects significant growth in insurance service performance, with expected revenue of CNY 28.2 billion in 2025, reflecting a year-on-year growth rate of 96.1% [3][8]. Earnings Forecast - The report revises the earnings per share (EPS) forecast for 2025-2027 to CNY 2.04, CNY 2.16, and CNY 2.32 respectively, up from previous estimates of CNY 1.69, CNY 1.86, and CNY 2.08 [8]. - The price-to-book (PB) target for 2025 is adjusted to 1.5x, corresponding to the target price of HKD 21.5 [8].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook based on its successful globalization strategy and structural improvement in profitability [5]. Core Insights - The company is expected to achieve significant growth in net profit from 11.17 billion to 22.27 billion RMB from 2025 to 2027, reflecting a year-on-year increase of 257.5%, 56.5%, and 27.3% respectively, with corresponding PE ratios of 35.4, 22.6, and 17.7 [5]. - The report highlights the company's successful expansion in both domestic and international markets, with substantial revenue growth driven by refined operations in China and rapid overseas market penetration [5][8]. - The diversification of the company's IP matrix has reduced reliance on a single IP, with plush toy revenue significantly increasing by 1276.2% year-on-year in the first half of 2025 [5]. Summary by Sections Market Data - The closing price of the stock is 322.2 HKD, with a market capitalization of 432.7 billion HKD and a total share count of 1.34 billion [2]. Financial Projections - Total revenue is projected to grow from 6.3 billion RMB in 2023 to 63.19 billion RMB in 2027, with a compound annual growth rate (CAGR) of 37% [7]. - The gross margin is expected to improve from 61.3% in 2023 to 73.0% in 2027, indicating enhanced profitability [7]. Growth Drivers - The company plans to expand its overseas store count to over 200 by the end of the year, targeting emerging markets in the Middle East, Central Europe, and Central South America [8]. - Innovations in product categories and a strong IP matrix are anticipated to continue driving revenue growth and market share [8]. Supply Chain and Production Capacity - The company has upgraded its supply chain through lean production and automation, increasing monthly production capacity for plush toys to 30 million units [6]. - Strategic plans include establishing six global production bases to enhance supply chain flexibility and responsiveness [6].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4][37] Core Insights - The company reported a revenue of 14.97 billion HKD for the first half of 2025, representing a year-on-year growth of 15.3%, while the net profit attributable to shareholders was 3.18 billion HKD, up 8.4% year-on-year [1][10] - The gross margin decreased by 1.9 percentage points to 27.1%, primarily due to increased labor costs from wage hikes for frontline workers and a significant rise in tax expenses [1][10] - The company maintained a high dividend payout, declaring an interim dividend of 1.38 HKD per share, a 10.4% increase from the previous year, with a payout ratio of approximately 59.6% [1][10] Revenue Performance - Revenue growth by product category showed that casual wear sales increased by 37.4%, while sportswear and underwear grew by 9.9% and 4.1%, respectively [2][22] - All four major clients experienced revenue growth, with Client A, B, C, and D increasing by 27.4%, 6.0%, 28.2%, and 14.7% respectively [2][24] - International markets showed strong demand, with sales in the US, Europe, and Japan growing by 35.8%, 19.9%, and 18.1% respectively, while domestic sales declined by 2.1% [2][28] Competitive Positioning - The company's growth outperformed that of its major clients, indicating an increase in market share, particularly as Nike is expected to recover in the coming year [3][32] - The company is the largest player in the industry and continues to enhance its competitive advantage, with significant capital expenditures aimed at expanding integrated production capabilities [3][35] - The new garment factory in Cambodia has commenced operations, and a second fabric factory in Vietnam is expected to start production by the end of the year, enhancing vertical integration and supply chain efficiency [3][35] Financial Forecast - The company forecasts net profits of 6.576 billion HKD, 7.461 billion HKD, and 8.403 billion HKD for 2025, 2026, and 2027, respectively, reflecting growth rates of 5.4%, 13.4%, and 12.6% [4][38] - The target price is set between 75 and 82 HKD, corresponding to a price-to-earnings ratio of 16-17.5x for 2025 [4][37]

Investment Rating - The report maintains a "Buy-A" rating for the company [2][7] Core Insights - The company reported a revenue of 14.715 billion yuan for H1 2025, a year-on-year increase of 7.56%, and a net profit of 1.104 billion yuan, up 5.04% year-on-year [3] - The growth in revenue and profit is attributed to the strong performance of the core business segment, which generated 10.107 billion yuan in revenue, a 29.9% increase year-on-year, and a profit contribution of 719 million yuan, up 53.3% year-on-year [4] - The company is focusing on optimizing its differentiated product structure, with a notable increase in sales of its "Bio+" high-end products, which saw a 51% year-on-year growth [5] Financial Performance - The company achieved a basic earnings per share (EPS) of 0.17 yuan and a diluted EPS of 0.17 yuan [2] - The net asset return rate (ROE) stands at 10.27% [2] - The projected net profits for 2025, 2026, and 2027 are 1.352 billion yuan, 1.483 billion yuan, and 1.599 billion yuan, respectively, with corresponding price-to-earnings (PE) ratios of 6.6, 6.1, and 5.6 [7] Business Segments - The core business segment's revenue growth is driven by strategic procurement optimization and the promotion of biological phosphate and potassium fertilizers, which effectively reduced overall fertilizer costs [4] - The growth business segment contributed 7.753 billion yuan in revenue, a 4.4% increase year-on-year, with a profit contribution of 420 million yuan, up 5.4% year-on-year [4] - The production business segment generated 3.202 billion yuan in revenue, an 8.4% increase year-on-year, but saw a profit decline of 15.6% due to rising raw material prices and a drop in urea market prices [4]

证券研究报告|港股公司点评报告 [Table_Date] 2025 年 08 月 28 日 [Table_Title] 上半年业绩超预期，幸运咖加速门店布局 [Table_Title2] 蜜雪集团(2097.HK) | [Table_DataInfo] 评级： | 增持 | 股票代码： | 2097 | | --- | --- | --- | --- | | 上次评级： | 增持 | 52 周最高价/最低价(港元)： | 568.0/290.0 | | 目标价格(港元)： | | 总市值(亿港元) | 1,747.76 | | 最新收盘价(港元)： | 460.4 | 自由流通市值(亿港元) | 694.67 | | | | 自由流通股数(百万) | 150.88 | [Table_Summary] 事件概述 2025H1，公司实现收入 148.75 亿元/+39.3%，归母净利润 26.93 亿元/+42.9%。 分析判断 ► 外卖大战+持续推新，驱动单店商品销售收入增长 今年 4 月份以来，京东、美团、饿了么等平台相继加大外卖补贴力度，现制茶饮和咖啡行业充分受益；同时， 公司持续推新，提升产品力，蜜雪冰城 ...

研究报告 Research Report 28 Aug 2025 医脉通 Medlive Technology (2192 HK) 25H1 业绩符合预期，应用 AI 技术提升平台能力 Performance meets expectations, applying AI technology to enhance platform capabilities [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$14.07 目标价 HK$15.00 HTI ESG 5.0-5.0-5.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$10.33bn / US$1.33bn 日交易额 (3 个月均值) US$6.90mn 发行股票数目 734.26mn 自由流通股 (%) 26% 1 年股价最高最低值 HK$17.04-HK$7.20 注：现价 HK$14.07 为 2025 ...

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of HKD 103.5 per share, indicating a potential upside from the current price of HKD 69.10 [2][5][14]. Core Insights - The company's revenue and profit for the first half of 2025 exceeded market expectations, driven by stabilization in domestic operations and rapid growth in overseas markets [3][10]. - In 1H25, the company achieved revenue of USD 160 million, representing a 33.1% increase year-over-year, with domestic revenue at USD 89.68 million (+0.6%) and overseas revenue at USD 71.67 million (+123.1%) [3][10][11]. - The share of overseas revenue reached 44.4%, up 17.9 percentage points, highlighting its importance as a key revenue source [3][10]. - The number of clear-aligner cases completed in 1H25 was 226,000, a 47.7% increase, with domestic cases growing by 14.0% and overseas cases surging by 103.5% [11][12]. Financial Performance - The gross margin for 1H25 was stable at 62.4%, while adjusted net profit increased by 84.8% to USD 19.47 million, resulting in a net margin of 12.1% [4][13]. - The company plans to implement aggressive market strategies in the second half of 2025 to maintain market share and continue its overseas expansion [5][14]. - Revenue forecasts for 2025 and 2026 have been raised to USD 340 million and USD 420 million, respectively, reflecting stronger-than-expected overseas growth [5][14]. Valuation Metrics - The report projects adjusted net profits of USD 26.75 million for 2025 and USD 32.80 million for 2026, with corresponding P/E ratios of 85x and 70x [5][14]. - The company is positioned as a leader in the clear-aligner market in China, with its overseas growth trajectory being increasingly validated [5][14].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has shown rapid growth in its brand "可复美" and the medical aesthetics approval process is accelerating [1] - For 1H2025, the company achieved a revenue of 3.11 billion yuan, a year-on-year increase of 22.5%, and a net profit attributable to shareholders of 1.18 billion yuan, up 20.2% year-on-year [4] - The company's online direct sales through e-commerce platforms have seen significant growth, with a 133.6% increase in revenue [5][7] - The company is expanding its offline store presence, with 24 brand stores established across various cities by the end of 1H2025 [7] - The gross margin slightly decreased by 0.7 percentage points to 81.7%, attributed to changes in product mix [7] - The company is expected to accelerate its performance in the second half of the year, driven by increased brand marketing efforts and the potential approval of new medical aesthetic products [9] Summary by Sections Financial Performance - In 1H2025, the company's professional skin care products generated revenue of 3.10 billion yuan, with functional skin care products contributing 2.41 billion yuan, a 24.2% increase year-on-year [5] - The adjusted net profit for 1H2025 was 1.21 billion yuan, reflecting a 17.4% year-on-year growth [4] Product and Brand Development - The "可复美" brand launched new products such as the "可复美胶原棒 2.0" and "焦点面霜," which have performed well in the market [6] - The "可丽金" brand introduced the upgraded "可丽金胶原大膜王 3.0," achieving top sales rankings on major e-commerce platforms [6] Market Expansion - The company has entered the Southeast Asian market by becoming the first Chinese functional skin care brand to enter Watsons in Malaysia [7] - The company is focusing on enhancing its online multi-platform layout and refining operations to capitalize on the rapid expansion of beauty categories on platforms like JD.com [7] Future Outlook - The company anticipates sustained growth in its skincare business, supported by the performance of existing star products and the introduction of new ones [8] - The approval of new medical aesthetic products is expected to contribute additional revenue, enhancing the company's growth trajectory [8]

交银国际研究 公司更新 业绩稳健，派息回馈持续，维持买入 买入 1 年股价表现 8/24 12/24 4/25 8/25 -20% -10% 0% 10% 20% 30% 40% 50% 3808 HK 恒生指数 股份资料 | 重卡 | 收盘价 | | 目标价 | | 潜在涨幅 | 2025 年 8 月 28 日 | | --- | --- | --- | --- | --- | --- | --- | | 港元 | | 23.32 | 港元 | 26.45 | +13.4% | | | 中国重汽 (3808 HK) | | | | | | | 李柳晓, PhD, CFA joyce.li@bocomgroup.com (852) 3766 1854 财务数据一览 | 年结12月31日 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 收入 (百万人民币) | 85,498 | 95,062 | 109,886 | 114,683 | 120,158 | | 同比增长 (%) | 43.9 | 11. ...